Indian Diabetes Market Report & Outlook For 2010-2015
With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction of the global sales, IMARC expects this market to surge in the future.
In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015.
Unlike Non-Insulin’s, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin.
Report Highlights
In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015.
Unlike Non-Insulin’s, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin.
Report Highlights
- A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to US$1.4 Billion by 2015.
- In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 306 Million. This represented a highly fragmented market with USV being the leading player with a 14% share.
- USV’s Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market with sales worth nearly US$ 10.5 Million
- IMARC expects around 15 new Drugs to be launched in the Non-Insulin Anti-diabetics market in the next five years. Seven of them are expected to be in the DPP-IV Inhibitor and GLP-1 Agonist classes.
- The Insulin Market was worth US$ 117 Million in 2009. Abbott was India’s biggest player accounting for 61% of the total sales.
- Sanofi Aventi’s Lantus (Insulin Glargine) represented one of the fastest growing drugs in the last five year and registered sales worth nearly 11 Million in 2009
- The total number of diabetes patients in India is expected to reach 87 Million by 2030. Around 56% of these patients will be from urban regions.
- Number of diabetes patients
- Diagnosis and treatment rates in India
- Diabetes market
- Non-Insulin Anti-diabetics market
- Glitazones
- Biguanides
- Sulphonylureas
- Alpha-Glycosidase Inhibitors
- DPP-IV Inhibhitors
- GLP-1 Agonists
- Glinides
- All other Non-Insulin Anti-diabetic classes
- Insulin market
- 2005-2009 sales and market shares of top players in the diabetes market
- 2005-2009 sales and market shares of top players in the Non-Insulin Anti-diabetics market
- 2005-2009 sales and market shares of top players in various Non-Insulin drug classes
- 2005-2009 sales of top drugs comprising the portfolio of key players in various Non-Insulin drug classes
- 2005-2009 sales and market shares of top players in the Insulin market
- 2005-2009 sales of top drugs comprising the portfolio of key players in the Insulin market.
- What is the total size of the diabetes population in India and what are it’s characteristics?
- What are the diagnosis and drug treatment rates for diabetes in India?
- What are the key factors driving the growth of diabetes medication in India?
- What is the size and breakup of the total diabetes market in India?
- What is the size and breakup of the total Non-Insulin diabetes market in India?
- What is the size and breakup of the total Insulin market in India?
- Who are the key players in the Indian diabetes market and how have they performed?
- What is the outlook of the Indian diabetes market in the next five years?
- Which new products are expected to be launched in the next five years?
- Which therapy classes will show the highest growth in the next five years?
- What are the road blocks in the Indian diabetes market?
1. EXECUTIVE SUMMARY
2. DIABETES DISEASE OVERVIEW
2.1 WHAT IS DIABETES?
2.2 DIABETES DIAGNOSIS AND TREATMENT
2.2.1 Diagnosis
2.2.2 Treatment
2.3 DIABETES COMPLICATIONS
3. WHY IS THE DIABETES MARKET SO LUCRATIVE IN INDIA
3.1 INDIA HAS THE LARGEST DIABETIC POPULATION IN THE WORLD.
3.2 INDIA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
3.3 IMPROVING DIAGNOSIS AND TREATMENT RATES
3.4 LARGE UNTAPPED MARKET
3.5 BRIGHT OUTLOOK FOR INNOVATIVE DRUGS
4. THE INDIAN DIABETES EPIDEMIOLOGY
4.1 TOTAL PREVALENCE
4.1.1 Type1 & Type2 Prevalence
4.1.2 Urban and Rural Prevalence
4.1.3 Prevalence of Diabetes by Sex
4.1.4 Prevalence of Diabetes by Age Group
4.1.5 Prevalence of Diabetes in Various Regions in India
4.2 DIAGNOSIS AND TREATMENT RATES IN INDIA
5. THE INDIAN DIABETES MARKET
5.1 MARKET TREND (2005-2009)
5.2 MARKET SEGMENTATION (2005-2009)
5.3 MARKET FORECASTS (2010-2015)
6. THE INDIAN NON-INSULIN ANTI-DIABETICS MARKET
6.1 MARKET TREND (2005-2009)
6.2 COMPETITIVE LANDSCAPE (2005-2009)
6.3 MARKET FORECASTS (2010-2015)
6.4 MARKET SEGMENTATION (2005-2015)
6.4.1 Glitazones
6.4.1.1 Market Trend (2005-2009)
6.4.1.2 Competitive Landscape
6.4.1.2.1 Share of Key Players
6.4.1.2.2 Portfolio of Key Players
6.4.1.3 Market Forecasts (2010-2015)
6.4.2 Biguanides
6.4.2.1 Market Trend (2005-2009)
6.4.2.2 Competitive Landscape
6.4.2.2.1 Share of Key Players
6.4.2.2.2 Portfolio of Key Players
6.4.2.3 Market Forecasts (2010-2015)
6.4.3 Sulphonylureas
6.4.3.1 Market Trend (2005-2009)
6.4.3.2 Competitive Landscape
6.4.3.2.1 Share of Key Players
6.4.3.2.2 Portfolio of Key Players
6.4.3.3 Market Forecasts (2010-2015)
6.4.4 Alpha-Glycosidase Inhibitors
6.4.4.1 Market Trend (2005-2009)
6.4.4.2 Competitive Landscape
6.4.4.2.1 Share of Key Players
6.4.4.2.2 Portfolio of Key Players
6.4.4.3 Market Forecasts (2010-2015)
6.4.5 Dpp-IV Inhibitors
6.4.5.1 Market Trend (2008-2009)
6.4.5.2 Competitive Landscape
6.4.5.2.1 Share of Key Players
6.4.5.2.2 Portfolio of Key Players
6.4.5.3 Market Forecasts (2010-2015)
6.4.6 Glinides
6.4.6.1 Market Trend (2005-2009)
6.4.6.2 Competitive Landscape
6.4.6.2.1 Share of Key Players
6.4.6.2.2 Portfolio of Key Players
6.4.6.3 Market Forecasts (2010-2015)
6.4.7 Glp-1 Agonists
6.4.7.1 Market Trend (2008-2009)
6.4.7.2 Competitive Landscape
6.4.7.2.1 Share of Key Players
6.4.7.2.2 Portfolio of Key Players
6.4.7.3 Market Forecasts (2010-2015)
6.4.8 All other Classes
6.4.8.1 Market Trend (2005-2009)
6.4.8.2 Competitive Landscape
6.4.8.2.1 Share of Key Players
6.4.8.2.2 Portfolio of Key Players
6.4.8.3 Market Forecasts (2010-2015)
7. THE INDIAN INSULIN MARKET
7.1 MARKET TREND (2005-2009)
7.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
7.3 MARKET SEGMENTATION BY MODE OF ACTION
7.4 COMPETITIVE LANDSCAPE
7.4.1 Share of key Players
7.4.2 Portfolio of Key Players
7.5 MARKET FORECASTS (2010-2015)
8. ROAD BLOCKS
8.1 LOW AVERAGE PER PATIENT SPENDING ON DIABETES DRUGS
8.2 PREFERENCE FOR INEXPENSIVE AND OLDER DRUG CLASSES
8.3 HIGHLY FRAGMENTED AND ‘GENERICIZED’ MARKET
8.4 LOW RATES OF DRUG TREATED POPULATION IN RURAL AREAS
2. DIABETES DISEASE OVERVIEW
2.1 WHAT IS DIABETES?
2.2 DIABETES DIAGNOSIS AND TREATMENT
2.2.1 Diagnosis
2.2.2 Treatment
2.3 DIABETES COMPLICATIONS
3. WHY IS THE DIABETES MARKET SO LUCRATIVE IN INDIA
3.1 INDIA HAS THE LARGEST DIABETIC POPULATION IN THE WORLD.
3.2 INDIA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
3.3 IMPROVING DIAGNOSIS AND TREATMENT RATES
3.4 LARGE UNTAPPED MARKET
3.5 BRIGHT OUTLOOK FOR INNOVATIVE DRUGS
4. THE INDIAN DIABETES EPIDEMIOLOGY
4.1 TOTAL PREVALENCE
4.1.1 Type1 & Type2 Prevalence
4.1.2 Urban and Rural Prevalence
4.1.3 Prevalence of Diabetes by Sex
4.1.4 Prevalence of Diabetes by Age Group
4.1.5 Prevalence of Diabetes in Various Regions in India
4.2 DIAGNOSIS AND TREATMENT RATES IN INDIA
5. THE INDIAN DIABETES MARKET
5.1 MARKET TREND (2005-2009)
5.2 MARKET SEGMENTATION (2005-2009)
5.3 MARKET FORECASTS (2010-2015)
6. THE INDIAN NON-INSULIN ANTI-DIABETICS MARKET
6.1 MARKET TREND (2005-2009)
6.2 COMPETITIVE LANDSCAPE (2005-2009)
6.3 MARKET FORECASTS (2010-2015)
6.4 MARKET SEGMENTATION (2005-2015)
6.4.1 Glitazones
6.4.1.1 Market Trend (2005-2009)
6.4.1.2 Competitive Landscape
6.4.1.2.1 Share of Key Players
6.4.1.2.2 Portfolio of Key Players
6.4.1.3 Market Forecasts (2010-2015)
6.4.2 Biguanides
6.4.2.1 Market Trend (2005-2009)
6.4.2.2 Competitive Landscape
6.4.2.2.1 Share of Key Players
6.4.2.2.2 Portfolio of Key Players
6.4.2.3 Market Forecasts (2010-2015)
6.4.3 Sulphonylureas
6.4.3.1 Market Trend (2005-2009)
6.4.3.2 Competitive Landscape
6.4.3.2.1 Share of Key Players
6.4.3.2.2 Portfolio of Key Players
6.4.3.3 Market Forecasts (2010-2015)
6.4.4 Alpha-Glycosidase Inhibitors
6.4.4.1 Market Trend (2005-2009)
6.4.4.2 Competitive Landscape
6.4.4.2.1 Share of Key Players
6.4.4.2.2 Portfolio of Key Players
6.4.4.3 Market Forecasts (2010-2015)
6.4.5 Dpp-IV Inhibitors
6.4.5.1 Market Trend (2008-2009)
6.4.5.2 Competitive Landscape
6.4.5.2.1 Share of Key Players
6.4.5.2.2 Portfolio of Key Players
6.4.5.3 Market Forecasts (2010-2015)
6.4.6 Glinides
6.4.6.1 Market Trend (2005-2009)
6.4.6.2 Competitive Landscape
6.4.6.2.1 Share of Key Players
6.4.6.2.2 Portfolio of Key Players
6.4.6.3 Market Forecasts (2010-2015)
6.4.7 Glp-1 Agonists
6.4.7.1 Market Trend (2008-2009)
6.4.7.2 Competitive Landscape
6.4.7.2.1 Share of Key Players
6.4.7.2.2 Portfolio of Key Players
6.4.7.3 Market Forecasts (2010-2015)
6.4.8 All other Classes
6.4.8.1 Market Trend (2005-2009)
6.4.8.2 Competitive Landscape
6.4.8.2.1 Share of Key Players
6.4.8.2.2 Portfolio of Key Players
6.4.8.3 Market Forecasts (2010-2015)
7. THE INDIAN INSULIN MARKET
7.1 MARKET TREND (2005-2009)
7.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
7.3 MARKET SEGMENTATION BY MODE OF ACTION
7.4 COMPETITIVE LANDSCAPE
7.4.1 Share of key Players
7.4.2 Portfolio of Key Players
7.5 MARKET FORECASTS (2010-2015)
8. ROAD BLOCKS
8.1 LOW AVERAGE PER PATIENT SPENDING ON DIABETES DRUGS
8.2 PREFERENCE FOR INEXPENSIVE AND OLDER DRUG CLASSES
8.3 HIGHLY FRAGMENTED AND ‘GENERICIZED’ MARKET
8.4 LOW RATES OF DRUG TREATED POPULATION IN RURAL AREAS
LIST OF FIGURES
Figure 2:1: The impact of Diabetes in the Human Body
Figure 2:2: Diabetes Complications
Figure 3:1: Global: Breakup of Patients by Region, (in %) 2010 & 2030
Figure 3:2: India: Tapped and Untapped Diabetes Market, (in Million US$), 2010
Figure 4:1: India: Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:2: India: Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:3: India: Total Number of Type1 Diabetes Patients* (in Million), 2005 & 2010
Figure 4:4: India: Total Number of Type-1 Diabetes Patients* (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:5: India: Total Number of Type 2 Diabetes Patients* (in Million), 2005 & 2010
Figure 4:6: India: Total Number of Type-2 Diabetes Patients* (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:7: India (Urban & Rural): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:8: India (Urban & Rural): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:9: India: Breakup of Diabetes Patients* by Urban/Rural Regions, (in %), 2010 & 2030
Figure 4:10: India (Male & Female): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:11: India (Male & Female): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:12: India: Breakup of Diabetes Patients by Sex, (in %), 2010 & 2030
Figure 4:13: India: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 4:14: India: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 4:15: India: Breakup of Diabetes Patients by Age Group, (in %), 2010 & 2030
Figure 4:16: Prevalence of Diabetes across various regions in India
Figure 4:17: India: Total Diabetes Diagnosed & Drug Treated Population*, 2005, 2010 & 2015
Figure 5:1: India: Diabetes Market, (in Million US$), 2005-2009
Figure 5:2: India: Diabetes Market, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 5:3: India: Diabetes Market, (in Million US$), 2010-2015
Figure 5:4: India: Diabetes Market Forecast, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 6:1: India: Non-Insulin Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:2: India: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:3: India: Non-Insulin Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:4: India: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Classes (in %),
Figure 6:5: India: Non-Insulin Anti-diabetics Market Forecast, Value Shares of Key Classes (in %), 2015
Figure 6:6: India: Glitazones Anti-diabetic Sales, (in Million US$), 2005-2009
Figure 6:7: India: Glitazone Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:8: India: Glitazone Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:9: Biguanide Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:10: India: Biguanide Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:11: India: Biguanide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:12: India: Sulphonylurea Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:13: India: Sulphonylurea Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:14: India: Alpha-Glycosidase Inhibitor Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:15: India: Alpha-Glycosidase Inhibitor Market, Value Market Shares of Key Players (in %),
Figure 6:16: India: Alpha Glycosidase inhibitor Anti-diabetics Sales Forecast, (in Million US$),
Figure 6:17: India: DPP-IV Inhibitors Sales, (in Million US$), 2008 & 2009
Figure 6:18: India: DPP-IV Inhibitors, Value Market Shares of Key Players (in %), 2008 & 2009
Figure 6:19: India: DPP-IV Inhibitor Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:20: India: Glinides Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:21: India: Glinides Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:22: India: Glinides Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:23: India: Glp-1 Agonist Anti-diabetics Sales, (in 000’ US$), 2008 & 2009
Figure 6:25: India: Glp-1 Agonist Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:26: India: All other Classes Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:27: India: All Other Classes Anti-diabetics Market, Value Market Shares of Key Players
Figure 6:28: India: All other Anti-diabetics Classes Sales Forecast, (in Million US$), 2010-2015
Figure 7:1: India: Insulin Sales, (in Million US$), 2005-2009
Figure 7:2: India: Insulin Market, Value Market Shares of Key Molecules (in %),
Figure 7:3: India: Insulin Market, Value Market Shares by Mode of Action (in %), 2009
Figure 7:4: India: Insulin Market, Value Market Shares of Key Players (in %),
Figure 7:5: India: Insulin Sales Forecast, (in Million US$), 2010-2015
Figure 8:1: Average per patient spending on Diabetes Drugs by Major Developed and Emerging Markets, 2010
Figure 2:1: The impact of Diabetes in the Human Body
Figure 2:2: Diabetes Complications
Figure 3:1: Global: Breakup of Patients by Region, (in %) 2010 & 2030
Figure 3:2: India: Tapped and Untapped Diabetes Market, (in Million US$), 2010
Figure 4:1: India: Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:2: India: Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:3: India: Total Number of Type1 Diabetes Patients* (in Million), 2005 & 2010
Figure 4:4: India: Total Number of Type-1 Diabetes Patients* (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:5: India: Total Number of Type 2 Diabetes Patients* (in Million), 2005 & 2010
Figure 4:6: India: Total Number of Type-2 Diabetes Patients* (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:7: India (Urban & Rural): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:8: India (Urban & Rural): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:9: India: Breakup of Diabetes Patients* by Urban/Rural Regions, (in %), 2010 & 2030
Figure 4:10: India (Male & Female): Total Number of Diabetes Patients* (in Million), 2005 & 2010
Figure 4:11: India (Male & Female): Total Number of Diabetes Patients* Forecast (in Million), 2010, 2015, 2020, 2025 & 2030
Figure 4:12: India: Breakup of Diabetes Patients by Sex, (in %), 2010 & 2030
Figure 4:13: India: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 4:14: India: Total Number of Diabetes Patients* by Age Group (20-39), (40-59) & (60-79)
Figure 4:15: India: Breakup of Diabetes Patients by Age Group, (in %), 2010 & 2030
Figure 4:16: Prevalence of Diabetes across various regions in India
Figure 4:17: India: Total Diabetes Diagnosed & Drug Treated Population*, 2005, 2010 & 2015
Figure 5:1: India: Diabetes Market, (in Million US$), 2005-2009
Figure 5:2: India: Diabetes Market, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 5:3: India: Diabetes Market, (in Million US$), 2010-2015
Figure 5:4: India: Diabetes Market Forecast, Share of Non-Insulin Anti-diabetics and Insulin (in %),
Figure 6:1: India: Non-Insulin Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:2: India: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:3: India: Non-Insulin Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:4: India: Non-Insulin Anti-diabetics Market, Value Market Shares of Key Classes (in %),
Figure 6:5: India: Non-Insulin Anti-diabetics Market Forecast, Value Shares of Key Classes (in %), 2015
Figure 6:6: India: Glitazones Anti-diabetic Sales, (in Million US$), 2005-2009
Figure 6:7: India: Glitazone Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:8: India: Glitazone Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:9: Biguanide Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:10: India: Biguanide Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:11: India: Biguanide Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:12: India: Sulphonylurea Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:13: India: Sulphonylurea Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:14: India: Alpha-Glycosidase Inhibitor Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:15: India: Alpha-Glycosidase Inhibitor Market, Value Market Shares of Key Players (in %),
Figure 6:16: India: Alpha Glycosidase inhibitor Anti-diabetics Sales Forecast, (in Million US$),
Figure 6:17: India: DPP-IV Inhibitors Sales, (in Million US$), 2008 & 2009
Figure 6:18: India: DPP-IV Inhibitors, Value Market Shares of Key Players (in %), 2008 & 2009
Figure 6:19: India: DPP-IV Inhibitor Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:20: India: Glinides Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:21: India: Glinides Anti-diabetics Market, Value Market Shares of Key Players (in %),
Figure 6:22: India: Glinides Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:23: India: Glp-1 Agonist Anti-diabetics Sales, (in 000’ US$), 2008 & 2009
Figure 6:25: India: Glp-1 Agonist Anti-diabetics Sales Forecast, (in Million US$), 2010-2015
Figure 6:26: India: All other Classes Anti-diabetics Sales, (in Million US$), 2005-2009
Figure 6:27: India: All Other Classes Anti-diabetics Market, Value Market Shares of Key Players
Figure 6:28: India: All other Anti-diabetics Classes Sales Forecast, (in Million US$), 2010-2015
Figure 7:1: India: Insulin Sales, (in Million US$), 2005-2009
Figure 7:2: India: Insulin Market, Value Market Shares of Key Molecules (in %),
Figure 7:3: India: Insulin Market, Value Market Shares by Mode of Action (in %), 2009
Figure 7:4: India: Insulin Market, Value Market Shares of Key Players (in %),
Figure 7:5: India: Insulin Sales Forecast, (in Million US$), 2010-2015
Figure 8:1: Average per patient spending on Diabetes Drugs by Major Developed and Emerging Markets, 2010
LIST OF TABLES
Table 2 1: Diagnosis of Diabetes
Table 3 1: Statistics of Top Emerging and Developed Diabetes Markets, 2010 & 2030
Table 3 2: Statistics of Top Emerging and Developed Diabetes Markets, 2009
Table 3 3: Drugs Expected to be launched in the Indian Diabetes Market, 2010-2015
Table 4 1: Prevalence of Type-1 & Type2 Diabetes in India
Table 4 2: India: Total Type-2 Diabetes Diagnosed & Drug Treated Population, 2005, 2010 & 2015
Table 5 1: India: Contribution of Non-Insulin Anti-diabetics & Insulin towards Total Growth,
Table 6 1: India: Non-Insulin Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 2: India: Non-Insulin Anti-diabetics Market, Sales of Key Classes (in 000’ US$),
Table 6 3: India: Non-Insulin Anti-diabetics Market, Value Shares of Key Classes (in %),
Table 6 4: India: Non-Insulin Anti-diabetics Market Forecasts, Sales of Key Classes (in 000’ US$),
Table 6 5: India: Non-Insulin Anti-diabetics Market Forecasts, Value Shares of Key Classes (in %),
Table 6 6: India: Glitazone Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 7: India: Sun Pharma’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 8: India: USV’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 9: India: Micro lab’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 10: India: Piralmal’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 11: India: Daichi’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 12: India: Biguanide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 6 13: India: USV’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 14: India: Sun Pharma’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 15: India: Franco Indian’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 16: India: Piralmal’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 17: India: Panacea Biotech’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 18: India: Sulphonylurea Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 19: India: Sulphonylurea Anti-diabetes, Value Market Shares of Key Players (in %),
Table 6 20: India: Sanofi Aventis Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 21: India: Dr Reddy’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 22: India: USV’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 23: India: Serviers’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 24: India: Piramal’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 25: India: Alpha-Glycosidase Inhibitor Market, Sales of Key Players (in 000’ US$),
Table 6 26: India: Bayer’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 27: India: Daiichi’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 28: India: Sun Pharma’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 29: India: Glenmark’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 30: India: Daichi’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 31: India DPP-IV Inhibitors, Sales of Key Players (in 000’ US$),
Table 6 32: India: MSD’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 33: India: Novartis’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 34: India: USV’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 35: India: Glinides Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 36: India: Abbot’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 37: India: Torrent’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 38: India: Glenmark’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 39: India: Orchid’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 40: India: Glp-1 Agonist Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 41: India: Lilly’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 42: India: All Other Classes Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 43: India: Piramal’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 44: India: Fourt’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009
Table 6 45: India: Charak Pharma’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 46: India: Intas’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009
Table 6 47: India: Himalaya’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 7 1: India: Insulin Value Shares by Molecule (in 000’ US$), 2005-2009
Table 7 2: India: Insulin Value Shares by Molecule (in %), 2005-2009
Table 7 3: India: Insulin Value Sales by Mode of Action (in 000’US$), 2005-2009
Table 7 4: India: Insulin Value Shares by Mode of Action (in %), 2005-2009
Table 7 5: India: Insulin Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 7 6: India: Abott’s/Novo Nordisk’s Insulin Portfolio Sales (in 000’ US$),
Table 7 7: India: Lilly’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 8: India: Sanofi Aventis’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 9: India: Biocon’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 10: India: Wockhardt Insulin Portfolio Sales (in 000’ US$), 2005-2009
COMPANIES MENTIONED
USV
Sun Pharma
Franco Indian
Piramal
Panacea Biotec
Micro Labs
Daiichi
Sanofi-Aventis
Dr Reddys Lab
Servier
Bayer
Glenmark
Lupin
Msd
Novartis
Fourts
Charak Pharma
Intas
Himalaya
Abbott
Torrent
Orchid Chemicals & Pharmaceuticals
Lilly
PRODUCTS MENTIONED
Glimepiride+Metformin
Glipizide+Metformin
Glibenclami
Metformin
Glimepiride+Metformin
Metformin+Voglibose
Glipizide+Metformin
Gliciazide+Metformin
Glimepiride+Metformin
Glibenclamide
Glimepiride+Pioglitazone+ Metaformin
Pioglitazone
Metformin+Pioglitazone
Glimepiride+Pioglitazone+Metaformin
Metformin Pioglitazone
Glimepiride+Pioglitazone
Melformin+ Rosiglitazone
Glimepiride
Gliclazide
Glipizlde
Glieiazide+Pioglitazone
Acarbose
Voglibose
Miglitol
Sitagliptin
Metformin+Sitagliptin
Vildagliptin
Metformin+Vildagliptin
Mecobalami
Gymnema
Repaglinide
Nateglinide
Metformin+Nateglinide
Exenatide
Exenatide
Exenatide LAR
Liraglutide
Lixisenatide
Taspoglutide
Albiglutide
LY-2189265
Alogliptin
Saxagliptin
Linagliptin
Glycomet-Gp
Duotrol
Glycomet
Glucored
Gemer
Volibo-M
Glipimet
Glyciphage
Claz-M
Diabetrol
Gluformin
Glurib-M
Metica
Glizid-M
Metlong
Biotec
Triglucored Forte
Gemer-P
Pioglit
Pioglit-Mf
Triclazone
Pioz
Pioz-MfG
Pioz-Mf
Triglycomet
Pioz-G
Tripride
Rgm
Pionorm
Pionorm-M
Rosinorm-M
Tribet
Diabetrol-3D
Piozone
Piozone-M
Piozone-G
Pioglar
PioglarG
RiometTrio
Piocon-Forte
Amaryl
Daonil
Glimy
Reelide
Gp
Glynase Usv
Semi-Glynase
Glycor
Glycor-C
Diamicron
Glimer
Euglucon
Semi-Euglucon
Codica
Glucobay
Volix
Mierva
Volibo
Rebose
Mignar
Glucar
Vocarb
Misobit
Vobit
Januvia
Janumet
Galvus
Eucreas
Jalra
Jalra-M
Nervup
Rejunuron
Hyponidd
Rejunex Plus
Rejunex
Diabecon
Meshashringi
Novonorm
Eurepa
Glinate
Glinate-Mf
Repa
Rapilin
Byetta
Nesina
Onglyza
Ondero
Bydureon
Victoza
Diabetes
Insulin
Oral-antidiabetics
Biguanide Antidiabetics
Glitazone Antidiabetics
Sulpphonylurea Antidiabetics
Alpha-Glucosidase Inhibhitor Antidiabetics
Dpp-IV Inhibhitor Antidiabetics
Other Drugs for Diabetes
Glinide Antidiabetics
Glp-1 Agonist Antidiabetics
Table 2 1: Diagnosis of Diabetes
Table 3 1: Statistics of Top Emerging and Developed Diabetes Markets, 2010 & 2030
Table 3 2: Statistics of Top Emerging and Developed Diabetes Markets, 2009
Table 3 3: Drugs Expected to be launched in the Indian Diabetes Market, 2010-2015
Table 4 1: Prevalence of Type-1 & Type2 Diabetes in India
Table 4 2: India: Total Type-2 Diabetes Diagnosed & Drug Treated Population, 2005, 2010 & 2015
Table 5 1: India: Contribution of Non-Insulin Anti-diabetics & Insulin towards Total Growth,
Table 6 1: India: Non-Insulin Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 2: India: Non-Insulin Anti-diabetics Market, Sales of Key Classes (in 000’ US$),
Table 6 3: India: Non-Insulin Anti-diabetics Market, Value Shares of Key Classes (in %),
Table 6 4: India: Non-Insulin Anti-diabetics Market Forecasts, Sales of Key Classes (in 000’ US$),
Table 6 5: India: Non-Insulin Anti-diabetics Market Forecasts, Value Shares of Key Classes (in %),
Table 6 6: India: Glitazone Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 7: India: Sun Pharma’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 8: India: USV’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 9: India: Micro lab’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 10: India: Piralmal’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 11: India: Daichi’s Glitazone Portfolio Sales (in 000’ US$), 2005-2009
Table 6 12: India: Biguanide Anti-diabetics Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 6 13: India: USV’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 14: India: Sun Pharma’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 15: India: Franco Indian’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 16: India: Piralmal’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 17: India: Panacea Biotech’s Biguanide Portfolio Sales (in 000’ US$),
Table 6 18: India: Sulphonylurea Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 19: India: Sulphonylurea Anti-diabetes, Value Market Shares of Key Players (in %),
Table 6 20: India: Sanofi Aventis Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 21: India: Dr Reddy’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 22: India: USV’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 23: India: Serviers’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 24: India: Piramal’s Sulphonylurea Anti-diabetics Portfolio Sales (in 000’ US$),
Table 6 25: India: Alpha-Glycosidase Inhibitor Market, Sales of Key Players (in 000’ US$),
Table 6 26: India: Bayer’s Alpha-Glycosidase Inhibitor Portfolio Sales (in 000’ US$),
Table 6 27: India: Daiichi’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 28: India: Sun Pharma’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 29: India: Glenmark’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 30: India: Daichi’s Alpha-Glycosidase Inhibhitor Portfolio Sales (in 000’ US$),
Table 6 31: India DPP-IV Inhibitors, Sales of Key Players (in 000’ US$),
Table 6 32: India: MSD’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 33: India: Novartis’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 34: India: USV’s DPP-IV Inhibitor Portfolio Sales (in 000’ US$), 2008 & 2009
Table 6 35: India: Glinides Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 36: India: Abbot’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 37: India: Torrent’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 38: India: Glenmark’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 39: India: Orchid’s Glinides Portfolio Sales (in 000’ US$), 2005-2009
Table 6 40: India: Glp-1 Agonist Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 41: India: Lilly’s Glp-1 Agonist Portfolio Sales (in 000’ US$)
Table 6 42: India: All Other Classes Anti-diabetics Market, Sales of Key Players (in 000’ US$),
Table 6 43: India: Piramal’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 44: India: Fourt’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009
Table 6 45: India: Charak Pharma’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 6 46: India: Intas’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$), 2005-2009
Table 6 47: India: Himalaya’s All other Anti-diabetics Classes Portfolio Sales (in 000’ US$),
Table 7 1: India: Insulin Value Shares by Molecule (in 000’ US$), 2005-2009
Table 7 2: India: Insulin Value Shares by Molecule (in %), 2005-2009
Table 7 3: India: Insulin Value Sales by Mode of Action (in 000’US$), 2005-2009
Table 7 4: India: Insulin Value Shares by Mode of Action (in %), 2005-2009
Table 7 5: India: Insulin Market, Sales of Key Players (in 000’ US$), 2005-2009
Table 7 6: India: Abott’s/Novo Nordisk’s Insulin Portfolio Sales (in 000’ US$),
Table 7 7: India: Lilly’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 8: India: Sanofi Aventis’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 9: India: Biocon’s Insulin Portfolio Sales (in 000’ US$), 2005-2009
Table 7 10: India: Wockhardt Insulin Portfolio Sales (in 000’ US$), 2005-2009
COMPANIES MENTIONED
USV
Sun Pharma
Franco Indian
Piramal
Panacea Biotec
Micro Labs
Daiichi
Sanofi-Aventis
Dr Reddys Lab
Servier
Bayer
Glenmark
Lupin
Msd
Novartis
Fourts
Charak Pharma
Intas
Himalaya
Abbott
Torrent
Orchid Chemicals & Pharmaceuticals
Lilly
PRODUCTS MENTIONED
Glimepiride+Metformin
Glipizide+Metformin
Glibenclami
Metformin
Glimepiride+Metformin
Metformin+Voglibose
Glipizide+Metformin
Gliciazide+Metformin
Glimepiride+Metformin
Glibenclamide
Glimepiride+Pioglitazone+ Metaformin
Pioglitazone
Metformin+Pioglitazone
Glimepiride+Pioglitazone+Metaformin
Metformin Pioglitazone
Glimepiride+Pioglitazone
Melformin+ Rosiglitazone
Glimepiride
Gliclazide
Glipizlde
Glieiazide+Pioglitazone
Acarbose
Voglibose
Miglitol
Sitagliptin
Metformin+Sitagliptin
Vildagliptin
Metformin+Vildagliptin
Mecobalami
Gymnema
Repaglinide
Nateglinide
Metformin+Nateglinide
Exenatide
Exenatide
Exenatide LAR
Liraglutide
Lixisenatide
Taspoglutide
Albiglutide
LY-2189265
Alogliptin
Saxagliptin
Linagliptin
Glycomet-Gp
Duotrol
Glycomet
Glucored
Gemer
Volibo-M
Glipimet
Glyciphage
Claz-M
Diabetrol
Gluformin
Glurib-M
Metica
Glizid-M
Metlong
Biotec
Triglucored Forte
Gemer-P
Pioglit
Pioglit-Mf
Triclazone
Pioz
Pioz-MfG
Pioz-Mf
Triglycomet
Pioz-G
Tripride
Rgm
Pionorm
Pionorm-M
Rosinorm-M
Tribet
Diabetrol-3D
Piozone
Piozone-M
Piozone-G
Pioglar
PioglarG
RiometTrio
Piocon-Forte
Amaryl
Daonil
Glimy
Reelide
Gp
Glynase Usv
Semi-Glynase
Glycor
Glycor-C
Diamicron
Glimer
Euglucon
Semi-Euglucon
Codica
Glucobay
Volix
Mierva
Volibo
Rebose
Mignar
Glucar
Vocarb
Misobit
Vobit
Januvia
Janumet
Galvus
Eucreas
Jalra
Jalra-M
Nervup
Rejunuron
Hyponidd
Rejunex Plus
Rejunex
Diabecon
Meshashringi
Novonorm
Eurepa
Glinate
Glinate-Mf
Repa
Rapilin
Byetta
Nesina
Onglyza
Ondero
Bydureon
Victoza
Diabetes
Insulin
Oral-antidiabetics
Biguanide Antidiabetics
Glitazone Antidiabetics
Sulpphonylurea Antidiabetics
Alpha-Glucosidase Inhibhitor Antidiabetics
Dpp-IV Inhibhitor Antidiabetics
Other Drugs for Diabetes
Glinide Antidiabetics
Glp-1 Agonist Antidiabetics
